O'Hair D P, Roza A M, Komorowski R, Moore G, McManus R P, Johnson C P, Adams M B, Pieper G M
Department of Transplant Surgery, Medical College of Wisconsin, Milwaukee 53226.
J Lipid Mediat. 1993 May;7(1):79-84.
Hyperacute rejection is a serious complication of xenogeneic organ transplantation. It is believed that platelets play a pivotal role in this phenomenon. In this study, we provide the first known evidence of the efficacy of the PAF receptor antagonist, tulopafant, in improvement in graft function and histology of discordant cardiac xenografts. Transplantation of guinea pig hearts into recipient rats resulted in hyperacute rejection. Pretreatment of recipient animals with tulopafant (but not indomethacin) extended rejection time by 4-5-fold. Histological examination revealed marked diminution of both interstitial hemorrhage and deposition of platelet and granulocytes in capillaries of cardiac xenografts when recipient animals were pretreated with tulopafant.
超急性排斥反应是异种器官移植的一种严重并发症。据信血小板在这一现象中起关键作用。在本研究中，我们提供了首个已知证据，证明血小板活化因子（PAF）受体拮抗剂妥洛帕泛在改善不协调性心脏异种移植物的移植物功能和组织学方面具有疗效。将豚鼠心脏移植到受体大鼠体内会导致超急性排斥反应。用妥洛帕泛（而非吲哚美辛）对受体动物进行预处理可使排斥反应时间延长4至5倍。组织学检查显示，当用妥洛帕泛对受体动物进行预处理时，心脏异种移植物毛细血管中的间质出血以及血小板和粒细胞沉积均显著减少。
